Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Gestational Stage and IFN-λ Signaling Regulate ZIKV Infection In Utero.

Cell host & microbe | 2017

Although Zika virus (ZIKV)-induced congenital disease occurs more frequently during early stages of pregnancy, its basis remains undefined. Using established type I interferon (IFN)-deficient mouse models of ZIKV transmission in utero, we found that the placenta and fetus were more susceptible to ZIKV infection at earlier gestational stages. Whereas ZIKV infection at embryonic day 6 (E6) resulted in placental insufficiency and fetal demise, infections at midstage (E9) resulted in reduced cranial dimensions, and infection later in pregnancy (E12) caused no apparent fetal disease. In addition, we found that fetuses lacking type III IFN-λ signaling had increased ZIKV replication in the placenta and fetus when infected at E12, and reciprocally, treatment of pregnant mice with IFN-λ2 reduced ZIKV infection. IFN-λ treatment analogously diminished ZIKV infection in human midgestation fetal- and maternal-derived tissue explants. Our data establish a model of gestational stage dependence of ZIKV pathogenesis and IFN-λ-mediated immunity at the maternal-fetal interface.

Pubmed ID: 28910635 RIS Download

Associated grants

  • Agency: NIAID NIH HHS, United States
    Id: U19 AI083019
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI073755
  • Agency: NCI NIH HHS, United States
    Id: P30 CA047904
  • Agency: NICHD NIH HHS, United States
    Id: R01 HD075665
  • Agency: NIAID NIH HHS, United States
    Id: T32 AI007172
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI104972
  • Agency: NICHD NIH HHS, United States
    Id: R01 HD091218
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK052574

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


HLA-G (4H84) (antibody)

RRID:AB_627938

This monoclonal targets Human HLA-G

View all literature mentions

Cytokeratin 19 antibody [EP1580Y] (antibody)

RRID:AB_2281020

This monoclonal targets Human Cytokeratin 19

View all literature mentions

ANXA3 Polyclonal Antibody (antibody)

RRID:AB_2759222

This polyclonal targets ANXA3

View all literature mentions

GraphPad Prism (software resource)

RRID:SCR_002798

Statistical analysis software that combines scientific graphing, comprehensive curve fitting (nonlinear regression), understandable statistics, and data organization. Designed for biological research applications in pharmacology, physiology, and other biological fields for data analysis, hypothesis testing, and modeling.

View all literature mentions

Vero (cell line)

RRID:CVCL_0059

Cell line Vero is a Spontaneously immortalized cell line with a species of origin Chlorocebus sabaeus

View all literature mentions

C57BL/6J (organism)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions